Mr. Harris joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to Chief Commercial Officer in June 2019. In his current role, he is responsible for all worldwide commercial operations.
Prior to joining Ultragenyx in 2017, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc. At Crescendo he held various leadership positions, most recently as Vice President of Commercial, leading all aspects of marketing, sales, managed care and customer service. Mr. Harris previously served as Vice President of Pulmonology Marketing at Intermune, Inc. Earlier in his career he held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol Myers Squibb Company. In addition to the Crysvita®, Mepsevii®, and Dojolvi® launches, Mr. Harris has been involved in the launches of Tarceva®, Tysabri® and Vectra-DA®. To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy.
Mr. Harris serves on the Board of Directors of Denali Therapeutics.
Mr. Harris received his Masters of Business Administration at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.
